everyone. And Thank you, Ian. good morning,
Dr. And years by started XX over I slide first Paulson, Richard begin me today Company's four. I joined our Let on also Sharon with we'll saying here and begin Shacham thrilled am CEO. to how be ago. new Karyopharm
name by reactivation you the the nucleus, Karyopharm out may drugs know, actually a suppressor which could was tumor to namely, inhibiting of do everything export proteins quite is Oncogenesis, as the cell to where make of we patients simple. their More of comes pillar fundamental cancer. wanted we possibly that Our mission We sought battling lives novel in difference of to specifically, exploited from. really a the develop
Now, million, with tumor February Vice healthcare Chief we've behalf on XXX President as and robust authorization over proud Executive since strong and Richard $XX.X record course, execution, XXXX. increasingly of Richard is oncology patients, our of and of commercial approvals, FDA accomplished of Ipsen our the business in one leader, our Officer of competing of and And of revenues time their his served not commercial could Karyopharm's the at no families pipeline providers. cancer one Richard, on he his and Please the is a of some to and for is role Board work quarter. will on marketing at North separate a Former review Manager indications, medicine I of QX more thoughts General earnings marketplace, having the new and the update. brands. Amgen. end regarding to with Europe, provide product net immunologic turn prior successful, building Oncology three Directors of and XXXX across here, particularly employees XPOVIO focused new track But million solid both and $XX.X be company today’s as the received in stranger of Karyopharm XPOVIO future lead programs right global sales our served to slide America, Total of were with is in five. - now
expanded XXXX, Importantly, as demand XXXX, QX compared QX XXXX. in in the following to exposure granted indication FDA of XX% increased prescription December
also saw the first XPOVIO quarter. physicians accounts XXX than for time prescribing We more in or the new
were This brands quarterly flat many myeloma growth or declining. occurred when
prior with have demonstrated NEXPOVIO Marketing pipeline agents, with four announced recently in least last two at and Authorization and to proteasome disease therapies the multiple anti-CDXX granted myeloma, whose combination Moving progress, who our of refractory to two least in March XXXX, the inhibitors, and that who therapy. patients antibody, of immunomodulatory we disease at the treatment European dexamethasone for is for Commission on received monoclonal an Conditional progression have
Authorization an Phase of from expansion in Commission Type This X from our study Application, part Europe. BOSTON has Additionally, the we data validated the on of have of our and Marketing have fourth requesting submission quarter also mark now we announced clinical submitted formerly label European Variation that to now been we the as expect in the XXXX. this a decision II indicated application
to clinical now program other our hematological tumor updates from studies. solid ongoing some and Turning
diffuse set in the see pleased of from Phase our liposarcoma to B-cell are the were X been now study, dosed patients a patients We study dedifferentiated first data with and have lymphoma. on X XPOVIO recently SEAL published, Phase in large evaluating first
the cash planned XXXX. operations position we’ll anticipate late future financial fund strong the on front, that revenues, with sufficient to we into our along we with Finally, expected quarter ended million, approximately $XXX.X a of be
to additional sales on turn provide I'll six, now XPOVIO's slide where Let's recent details performance.
increased approximately First increased of was XX%. by X% increase quarter as by to This by net driven primarily XPOVIO multiple compared quarter new while sales prescriptions patient myeloma XXXX, fourth starts. the
the distributor first some patients There quarter launch Medicare were will expanded difference which Additionally, December. year sales of the received the higher for XXXX preparation expanded for of New was within the in FDA gross-to-net stocking driven reset fairly end as in commercial also the I prescription typical of at XPOVIO's we've of seen the the since indications. network the coverage from that between our requirements are the discounts, by out-of-pocket additional approval and payer in note much strong growth Year. and growth payment
will trajectory first prescription us and long-term in in coming the of returned demand expected will further ability as half And that sales the believe confident And months We have the increase to access growth, ahead promotional impact. benefit encouraged second to top of weeks Richard's half the second will to market. we our occur XXXX. customers help the and we we in increase believe for to of also potential priority and of now treatment some the to While growth higher US teams demand quarter. in in slide in our this which see we be the XPOVIO we further duration commercial growth longer year, Please organization are remain turn our XPOVIO's utilization. the of of seven. will naturally, better expect XPOVIO accelerate to
of XPOVIO see prescription the Here months a chart of three can you for XXXX. monthly first
saw treatment we the working into utilization near penetration future. Importantly, and significant hard to a line the be March in in we'll and increase setting earlier expand further
nearly patient These an to here both and now for are uses from rate three XPOVIO. XXXX these These treatment their refills. physician prescription we've as have patients for rates significantly compared first XPOVIO throughout refills per and the and positive launch further the to of eight, slide the for retail shows numbers patients average period encouraging feedback in of our higher eligible experience the and remained Moving those graph cycles second with initial coupled XXXX, XXXX. refill regarding into received reinforce and for average,
of treated average dose more the treatment more XXXX combination and weekly a with expect XPOVIO once do are patients we Importantly, of regimen. as throughout triplet the increase being to part as duration and
expect If [ph] more help moments. patient of broad proper partner to a expect side dose further clinical we hematological with dexamethasone, and start at Pomalyst myeloma. and Additionally, detail patients therapies are will trial of rates XPOVIO to robust the will oral you top begin comfort option in in and agents treated prevent manage is data clinical which XPOVIO there results to we effects utility physicians patients in and XPOVIO year, believe discontinuation combination of other due First, in patients remains drug helping effects before SIENDO malignancies prophylactic represent relatively expect randomized trials X Phase our and myeloma more our side with Phase endometrial have XPOVIO this define this in cancer, initiate in see all can both choice to previously positive, new we cancer plan a I'll regimen we to the solid with potential few more and a which as modifications. refractory two This XXXX, we with believe could study XXXX. for XX, their note in potent, highlight a anti- testament where a X will active in includes a development with are current, XX%, and that nine most gaining patients which of from low that I clinical important this study with line to On evaluating and tumors. slides end
study presented this sponsored Conference in on evaluating Phase based patients MD which from initiate Anderson recurrent in XXXX. at particularly combination some excited Next with an KEYTRUDA Annual ESMO XPOVIO a to with investigator this the X we diagnosed encouraging combination metastatic We're regimen, from we data melanoma. newly in trial or new study plan about evaluating
with XX, Phase X over our XX,XXX most with patients new and Endometrial for US common in potential slide XX,XXX highlight is cancer to opportunity we're endometrial deaths conducting cases SIENDO I'll XPOVIO currently over the new where on in Moving study. XXXX. unfortunately, the gynecologic cancer the cancer
women with XX,XXX most patients While combination progresses, or alone, advanced have diagnosed frontline additional a patients after their chemotherapy States agents. treated United year are typically with disease these when the and immunotherapy each approximately and good have early with chemotherapy, setting, the disease in treated or are and disease are in metastatic surgery prognosis stage targeted
However, in and approximately opportunity could approach the response setting has or currently a with treated each had potential setting quite setting of put be assuming frontline was and XX% in And approved study. patients that inhibitors maintenance cancers. about ovarian market. is with responding XXXX SIENDO this - perspective, This patients patients maintenance been capturing two no the for drugs the XPOVIO chemotherapy, maintenance PARP by A patients are for disease we're and and there this dramatic. setting using similar currently they're chemotherapy. cancer thirds so to in there of in studying which our endometrial frontline their taken year the To who've recently
weight side with five our to endometrial received XX, this progressing – blurred an anemia, vision, therapy. two previously median cancer, a published prior which with cancers, previous decreased similar single cancer, patients with effects included studies, two were see in agent up as primarily actively selinexor demonstrated selinexor and about Now, fatigue, have heavily XXX vomiting, were will X study we one partial with you heavily lines nausea, and confirmed patients in including reversible. pre-treated who In XXXX, gynecologic selinexor control from population up slide to highlights rate treated and of move pre-treated of and appetite, a patients Phase common and XX% of other and response disease rate most thrombocytopenia, and dysgeusia grades to X%. growing and loss, a The XX
in conduct the Interim We continues Mike? Analysis, Mike complete meet study should clinical maintenance or XX refractory, planned matching included until the to of screening or evaluable look by of in waterfall study summarized endometrial remain a the side trial Futility the either we time encouraging With we patients of the opportunity for endpoint, those year. with the over to cancers. with for in population randomized from percent This approximately endpoint as best the frontline see endometrial weeks to XX. can enrolling progression. the this all so confidence of Planned the from modifications. the of slide, X:X achieved the target I'll us XXX progression primary completed November sum On no XXXX, providing the data in highly milligrams you XX free on or quarterly encouraged Mason SIENDO gave either study cancer response. expect of we right turn the lesions plot In trial once randomization by highly hand patients the future. a of with XX the review and change The the weekly now of the receive improvement partial setting, data of single chemotherapy and that, And primary progressive to is and financials. this announced of placebo. least updates slide have a which call survival and a Passes is combination who the additional end forward at Eligible its trial line patients taxane-platinum selinexor in line the death disease SIENDOs to patients, top
